Clik here to view.
San Diego Life Sciences Roundup: Receptos IPO, Isis, Versant, & More
Bruce V. Bigelow Some of San Diego’s public life sciences companies have been buoyed as the stock market has soared to new heights in recent weeks (for the year, the Dow is up 13 percent and the...
View ArticleClik here to view.
Avalon Ventures’ $495M Deal Grew from GSK Quest for Academic Inroads
Bruce V. Bigelow The partnership between Avalon Ventures and GlaxoSmithKline (NYSE: GSK), which is intended to invest as much as $495 million in 10 early stage life science companies in San Diego was...
View ArticleClik here to view.
San Diego Life Sciences Roundup: Avalon’s GSK Deal, Illumina, & More
Bruce V. Bigelow Even with the big BIO International Convention in Chicago this week, San Diego still managed to make life science headlines, as Avalon Ventures unveiled a pharma partnership that...
View ArticleClik here to view.
Automotive Cleantech Fallbrook Technologies Relocates Near Austin
Bruce V. Bigelow Fallbrook Technologies was founded in San Diego, and it spent 15 years working to commercialize its design for a new type of continuously variable transmission, with the potential to...
View ArticleClik here to view.
Abide Therapeutics and Merck Unveil Diabetes Drug Collaboration
Bruce V. Bigelow Abide Therapeutics, a two-year-old San Diego biopharmaceutical firm pioneering new ways to identify and validate drug targets among the serine hydrolase “superfamily” of enzymes, says...
View ArticleClik here to view.
San Diego Life Sciences Roundup: Topera, Afraxis, Trovagene, & More
Bruce V. Bigelow It was a week of deals, deals, and more deals for San Diego’s life sciences sector. Here’s my rundown. —San Diego’s Abide Therapeutics entered into a drug development collaboration...
View ArticleClik here to view.
San Diego’s RuiYi (aka Anaphore) Focuses Anew on Antibodies & China
Bruce V. Bigelow It’s been almost two years since Paul Grayson was named as CEO of San Diego’s Anaphore—more than enough time for the former Fate Therapeutics CEO to put a new strategy in place. The...
View ArticleClik here to view.
San Diego Life Sciences Roundup: Optimer, Ambit, AnaptysBio, & More
Bruce V. Bigelow [Clarification 5/17/13, 2:05 pm. See below.] Right on the same line with the original lede so you don’t waste space on a carriage return…Antibody drugs seemed to be the topic of the...
View ArticleClik here to view.
Isis Execs Upbeat as AstraZeneca Expands Cancer Drug Collaboration
Bruce V. Bigelow Executives at Carlsbad-based Isis Pharmaceuticals (NASDAQ: ISIS) were upbeat in a conference call this week, after the company reported encouraging news on several fronts. The company...
View ArticleClik here to view.
Using Frugal Business Model, Orphagen Targets Orphan Receptors
Juliet Preston The decline of venture capital investments in life sciences startups has provoked a lot of angst in the U.S., with many experts predicting a shortage of new drugs for the pharmaceutical...
View ArticleClik here to view.
San Diego Life Sciences Roundup: Isis, Elcelyx, Acutus, and More
Bruce V. Bigelow Much of the big news in San Diego’s life sciences community over the past week was coming out of Chicago, where the American Diabetes Association was holding its annual meeting. We’ve...
View ArticleClik here to view.
As ReVision Raises $55M, Domain’s Dovey Assesses Rusnano Gambit
Bruce V. Bigelow Almost 18 months ago, Domain Associates and the Russian state technology firm Rusnano agreed to jointly invest as much as $760 million in life sciences deals in the U.S. and Russia....
View ArticleClik here to view.
La Jolla Institute Extends 25-Year Partnership with Japanese Pharma
Bruce V. Bigelow [Corrected 8/01/13, 00:30 am. See below.] The La Jolla Institute for Allergy and Immunology says it has extended its industry-academic collaboration with the California-based...
View ArticleClik here to view.
Arena’s Expanded Marketing Deal with Eisai Has Broad Implications
Bruce V. Bigelow Arena Pharmaceuticals (NASDAQ: ARNA) rode a wave of investor enthusiasm after the San Diego company said last week it has expanded its commercialization agreement with the Japanese...
View ArticleClik here to view.
San Diego Life Sciences Roundup: Tandem, Sorrento, Volcano, & More
Bruce V. Bigelow [Updated 11/14/13 3:40 pm to show that Celladon postponed its IPO.] Another San Diego life sciences company completed its IPO, and at least one more local IPO (Biocept) is waiting in...
View ArticleClik here to view.
First Startup from Avalon-GSK Deal Raises $10M for Celiac Disease
Bruce V. Bigelow A collaboration formed earlier this year between San Diego’s Avalon Ventures and GlaxoSmithKline (NYSE: GSK) has hatched its first startup. Avalon partner Jay Lichter says the...
View ArticleClik here to view.
San Diego’s Genomatica Inks Development Deal for “Bio Butadiene”
Bruce V. Bigelow Genomatica, the San Diego industrial biotech, and the Brazilian petrochemical company Braskem have agreed to work together to commercialize technology needed to produce bio-based...
View ArticleClik here to view.
San Diego Life Sciences Roundup: Accelrys, Celladon’s IPO, and More
Bruce V. Bigelow A buyout offer for Accelrys, a new stem cell center of excellence, and an IPO. Not bad for one week of life sciences news. But wait, there’s more… —French software developer Dassault...
View ArticleClik here to view.
Celladon Could Go Far Under Servier Collaboration, Licensing Deal
Bruce V. Bigelow San Diego-based Celladon (NASDAQ: CLDN) said it has granted France’s Servier an option to license a new class of small-molecule drugs that could someday be used to treat type 2...
View ArticleClik here to view.
Partnership with AnaptysBio Gives Tesaro Entrée to Immuno-Oncology
Bruce V. Bigelow San Diego’s AnaptysBio has cut a deal with with Tesaro (NASDAQ: TSRO) that gives the Waltham, MA-based biopharmaceutical a new opening in the hot field of cancer immunotherapy. Under...
View Article
